OSE Immunotherapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-37.69	37.45	-23	-17.76	-16.85
Depreciation & Amortization	3.25	3.31	3.53	3.49	3.02
Stock-Based Compensation	1.5	2.09	1.75	2.73	2.94
Other Adjustments	-3.25	6.24	-0.98	-0.5	-0.7
Changes in Other Operating Activities	2.3	1.98	-0.84	-3.14	1.03
Operating Cash Flow	-34.03	48.44	-19.76	-18.25	-9.92
Operating Cash Flow Growth	-	-	-	-	-
Capital Expenditures	-0.1	-0.08	-0.02	-0.27	-0.47
Purchases of Investments	41.45	-46.83	-0.28	0	0
Other Investing Activities	-	-	-0.22	0.3	-0.36
Investing Cash Flow	41.36	-46.91	-0.51	0.03	-0.83
Long-Term Debt Issued	0.79	2.11	5.02	12.06	15.28
Long-Term Debt Repaid	-7.93	-6.25	-3.36	-1.8	-0.59
Net Long-Term Debt Issued (Repaid)	-7.14	-4.15	1.67	10.26	14.69
Issuance of Common Stock	0.07	1.16	11.66	-	0.27
Net Common Stock Issued (Repurchased)	0.07	1.16	11.66	-	0.27
Other Financing Activities	0.55	-0.47	-	-3.07	0.63
Financing Cash Flow	-6.51	-3.46	13.32	10.27	14.96
Net Cash Flow	0.81	-1.93	-6.95	-7.96	4.21
Free Cash Flow	-34.13	48.36	-19.78	-18.53	-10.39
Free Cash Flow Growth	-	-	-	-	-
FCF Margin	-1303.25%	69.21%	-888.19%	-101.22%	-39.50%
Free Cash Flow Per Share	-1.53	2.22	-1.01	-1.00	-0.57
Levered Free Cash Flow	-39.38	38.51	-18.66	-7.43	1.42
Unlevered Free Cash Flow	-32.38	33.58	-20.1	-18.14	-12.7